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INTRODUCTION 
Oral cancers broadly  includes  neoplasms arising  from buccal mucosa , tongue , 
lips , hard palate , soft palate , oropharynx , larynx , hypopharynx except the neoplasm 
arising from salaivary gland. Among this 90% comprises squamous cell carcinoma. 
Oral cancer is the most common cancer in India among men (11.28% of all 
cancer) and fifth among women (4.3% of all cancers ) and 3
rd
 most frequently occurring 
cancer in India among both men and women 
(1)
. 
 
Oral SCC is the 6
th
 leading cause of 
cancer worldwide. 
(2) 
Squamous cell carcinoma arises from the lining epithelium of oral  mucosa .          
Oral SCC is a more aggressive tumour and it has increased tendency to spread to cervical 
lymphnodes. Nodal metastasis also determines the prognosis and survival outcome of the 
patient. 
It is a multistep  carcinogenesis process  involving numerous oncogenes and 
tumour suppressor gene. Because of increased incidence and high recurrence rate  with 
increased morbidity and mortality, it is mandatory to understand the neoplastic 
transformation at sub cellular level
(3)
. 
Now many studies are going on to establish the various prognostic factors for oral 
SCC. Especially at the molecular level including p53 various tumour suppressor gene has 
been identified in the etiology of oral squamous cell carcinoma 
(4)
. 
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MASPIN – Mammary Serine Protease Inhibitor belongs to serine protease 
inhibitor family. Proteases which breaks down extracellular matrix and promotes tumour 
invasion and metastasis . But maspin being a proteases inhibitor which prevents 
metastasis and tumour progression . MASPIN also induces apoptosis of the tumour cells 
by the activation of CASPASE pathway
(5)
. MASPIN  has various implication in oral SCC 
not only in the form of tumour progression and metastasis but it also has role in  
tumorigenesis and differentition .  
MASPIN  also has its role in endothelial apoptosis (ie) antiangiogenic property. So  
targetted therapies are established against MASPIN to control  tumour angiogenesis and 
metastasis by that reduces the tumour progession 
(6)
. 
The main purpose of this study is to establish the interrelation ship between 
clinicopathological findings and MASPIN expression  and its prognostic impact. 
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AIMS AND OBJECTIVES 
1) To study the incidence of oral SCC in patients admitted in Govt.Stanley Medical 
College , Chennai during the period of  January 2016 to December 2016    
2) To identify the incidence of oral SCC in various sites. 
3) To study the clinicopathological features and various prognostic factors of oral SCC 
including age , sex, risk factors , histological grade , tumour staging  and  nodal 
metastasis. 
4) To  determine the immunohistochemical expression of MASPIN. 
5) To evaluate the level of MASPIN expression  in various grades of oral SCC. 
6) To compare the overall MASPIN expression  (OME) with various prognostic 
factors. 
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REVIEW OF LITERATURE 
EPIDEMIOLOGY : 
Oral SCC ranks 6
th
 among all cancers worldwide
(7)
 . It can arises from any part 
oral cavity but most commonly affected site is tongue ,floor of mouth
(11)
. It ususally 
arises from premalignant lesions. 
            There are various risk factors involved in origin of SCC among that tobacco 
chewing ,betal nut chewing ,alcohol is considered as most important risk factor
(8)
. 
          Oral SCC occurs  most common among men  than  in women because men are 
most commonly exposed  to risk factors such as moking , betal nut chewing and alcohol 
intake. The development of SCC also depends on the age and duration of exposure 
(9)
 . 
As age increases age related  mutagenic and epigenetic changes occurs. Various 
syndromes are associated with oral SCC namely Li Fraummeni syndrome , Plummer 
Vinsons Syndrome, Fanconi’s anaemia , Dyskeratosis Congenita,  Xeroderma 
Pigmentosa, Discoid Lupus Erythematosus, chemotherapy induced immunosupression  of 
organ  transplant(10) .            
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            The most common  site involved  is ventral surface of  tongue  and floor of 
mouth
(11)
 . The reason behind this is it is lined by non keratinized squamous epithelium. 
Since it is non keratinised the carcinogens easily penetrate , accumulate and affects the 
progenitor cells .These carcinogens constantly accumulate and bathe the tissues of floor 
of the mouth and tongue. 
ANATOMY: 
Head and neck is the most complex part of our body 
ORAL CAVITY:  The oral cavity is a multifaceted organization tailored to perform 
various functions including mastication, ingestion, taste sensation, immune surveillance 
and speech. 
            Oral cavity comprises of the roof, floor and lateral walls. The roof separates the 
oral cavity from nasal cavity by hard palate and soft palate. Floor is formed by the 
muscular diaphragm- mylohyoid muscle. The lateral Walls or cheek are formed by the 
muscle lined by mucosal layer. The cheek continues anteriorly as lips called as anterior 
fissure and posteriorly into Oropharynx. This opens into pharynx. Soft palate and tongue 
surrounds the  oropharynx. 
COMPONENTS:  
It can be divided into eight sub sites:  
1. Lip  
2. Buccal mucosa  
3. Lower alveolar ridge  
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4. Upper alveolar ridge  
5. Retro molar trigone (retro molar gingiva)  
6. Hard palate  
7. Anterior 2/3 of tongue and  
8. Floor of the mouth.  
 
FLOOR OF THE MOUTH:  
It is a horse shoe – shaped mucosal area between the gingiva of the lower alveolar 
ridge laterally or ventrally and the lateral border of the tongue medially, extending 
dorsally to the left and right tonsillar areas. The frenulum of the tongue which divides the 
tongue into right and left sides. It contains ostia of the sublingual and submandibular 
salivary glands.  
HARD PALATE:  
The roof of the oral cavity is formed by hard palate formed by portions of 
maxillary and palatine bones.  
RETRO MOLAR TRIGONE:  
It is a triangular mucosal surface that lined the ventral surface of the ascending 
mandibular ramus. 
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MICROANATOMY OF ORAL MUCOSA: 
The squamous epithelium lining the oral mucosa is composed of keratinocytes 
which is stratified. Basal cells are the one that helps to maintain the normal thickness of 
the epithelium by their constant replication. The basal cells are constituted by the 
organized units of stem cells and transit amplifying cells. The transit amplifying cells 
divide frequently in short intervals whereas the stem cells divide infrequently. 
 The oral squamous epithelium has a longer turn over time when compared  with 
gastrointestinal mucosa . It takes  about 25 days for buccal epithelium and 50 days for 
gingival epithelium
(12)
. Lamina propria that lies beneath the epithelium is composed of 
fibrous tissue with very  rich neurovascular supply. 
 The crucial factor for the homeostatic maintenance of oral mucosa is the interface 
between the epithelium and lamina propria. 
VARIATION IN THE LINING EPITHELIUM IN ORAL SITES 
Epithelial type Thickness Site 
Orthokeratinised  Thick Hard palate,gingiva 
Parakeratinised  Thick 
Gingival,dorsal Tongue, alveolar 
mucosa 
Non keratinised  Thick Buccal and labial mucosa 
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Non keratinised Thin 
Ventrolateral tongue,floor of the 
mouth,soft palate and gingival 
sulcus 
 
ORAL EPITHELIAL CELL KINETICS 
The oral epithelial cell proliferation index is the one exhibiting  high labelling 
index rate  of 11.7% in non keratinized lining mucosa than  the thick keratinized gingival 
mucosa, which showed an index of 8.5%
(13,14)
. 
NASAL CAVITY: 
Nasal cavity forms the uppermost part of the respiratory tract. It is formed of two 
nasal cavities which open into nares anteriorly, choanae  posteriorly and limited laterally 
by orbits. 
PHARYNX: 
The link between oral cavity and nasal cavities with larynx and esophagus in the 
neck is established by musculofascial half cylinder. They comprise nasopharynx, 
oropharynx and laryngopharynx. Retropharyngeal space is the loose connective tissue 
zone which separates pharynx from vertebral column. Skeletal muscle and fascia forms 
the pharyngeal wall. 
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NASOPHARYNX: 
The nasopharynx is the part formed between posterior apertures of nasal cavities 
or choanae and the level above soft palate. The roof and lateral walls are formed by 
domed vault of pharyngeal cavity which consists of sphenoid bone and basal parts of 
occipital bone. 
OROPHARYNX: 
Posterior opening of oral cavity is known as oropharynx. It is bound between 
inferior level of soft palate and upper part of epiglottis. The oropharynx is bound by 
posterior one third of tongue and lingual tonsil anteriorly , palatoglossal and 
palatopharyngeus muscle on both sides. 
TONSILS: 
The largest collection of lymphoid tissue in the oropharynx is  known as palatine 
tonsil. The lymphoid collection in the roof of nasopharynx is called as adenoids or 
pharyngeal tonsils. Lingual tonsil is present in posterior one third of tongue. 
LARYNGOPHARYNX: 
Laryngopharynx is bound between the margin of epiglottis and superior part of 
esophagus. It comprises two important anatomical landmarks. Anteriorly it forms 
mucosal pouches called as valleculae. The other one is pyriform fossa between the central 
part of larynx to lateral part of thyroid. 
LARYNX: 
Larynx forms the upper airway tract which continues as trachea inferiorly forming 
the lower respiratory tract. It has three large unpaired cartilages, three smaller cartilages, 
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fibroelastic membrane and numerous intrinsic muscles. It is a tubular structure lined by 
mucosa formed by superior margin of epiglottis anteriorly, aryepiglottic fold laterally and 
interarytenoid notch posteriorly. 
LYMPHATIC DRAINAGE OF ORAL CAVITY:  
The following are the three groups of nodes that are mainly involved: 
a. Jugulodigastric lymphnodes 
b. Submental lymphnodes  
c. Submandibular lymph nodes  
 Gingival lymph vessels drain to the submandibular lymph nodes, while those 
from lower incisor region drain to the submental nodes.  
 Vessels from palate mostly are drained by jugulodigastric lymph nodes, but 
some are drained by retropharyngeal nodes.  
 The rich lymphatic plexus in the lateral third of dorsum, lateral border, and part 
of ventral part of tongue drain into the ipsilateral submandibular lymph nodes.  
 Central lymph vessels run to bilateral submandibular nodes; some directly run 
to the jugulo-omohyoid nodes.  
 Jugulodigastric, Jugulo-omohyoid or the intermediate nodes unilaterally or 
bilaterally drain the lymphatics vessels from circumvallate papillae.  
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ETIOLOGY : 
The etiology of precancerous and cancerous lesions of oral and upper respiratory 
tract infection are multifactorial. The most common risk factor is tobacco use, smoking, 
snuffing or chewing , betal quid and high alcohol intake . The risk of oral SCC  increases 
to 80% by the usuage of tobacco and alcohol 
(20)
. 
TOBACCO: 
In India tobacco chewing is considered as main risk factor for oral and 
oropharyngeal malignancies in about 50%in men and about 90% of women. The risk 
intensifies and it is three and half times higher in smokers when compared to non 
smokers 
(15 ,21)
. It may be used in various forms like snuff dipping , chewing , smoking 
with cigars , beedies and pipes. 
IARC confined that tobacco contains more than 70 carcinogens.The most common 
among them is polycyclic hydrocarbons and nitrosamines
(16)
. The cytochrome p450 
oxidising enzyme is responsible for the formation of reactive carcinogenic intermediates. 
If these carcinogens fail to get detoxified , it forms the adducts between the carcinogenic 
agents and the keratinocyte DNA
(17)
.  
ARECA NUT : 
Few studies also shown that areca nut which contains calcium hydroxide when it 
combines with tobacco it increases the relative risk to 8.15 times as their risk is 1- 4 times 
without tobacco. When chewing it releases reactive oxygen species that induces 
mutation
(22)
. 
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SMOKING : 
            Smokers are more prone to develop oral and upper respiratory tract malignancies 
when compared to non smokers and the risk is  three and half times more in smokers .The 
risk is determined by the intensity and duration of smoking  more than 20 cigarretes/day 
for more than  20 years duration increases the risk of malignancy and also cessation of 
smoking decrease the risk of malignancy to three quarters . Smoking increases the 
prostaglandin levels and also it overexpresses various genes responsible for 
carcinogenesis 
(18, 23)
. 
ALCOHOL: 
Important carcinogen present in alcohol are nitrosamine, acrylide and 
polyphenols
(19)
. 
Ethanol when metabolized to acetaldehyde becomes mutagenic and act along with 
tobacco smoking in the oral carcinogenesis. Alcohol act as solvents and increases the 
permiability of carcinogens to oral mucosa
(24)
. 
INFECTION : 
Infection with HPV plays a vital role in a subset of Head and Neck cancers
(25,26,27)
. 
There is an increasing incidence in HPV associated oropharyngeal SCC 
(28) 
. HPV was 
detected more frequently in oropharyngeal SCC’s (in tonsils, base of tongue) in 
comparison with cancers of oral cavity or other HNSCC subsites
(26,27,29)
.  
Though more than 150 serotypes of HPV are present, infection  with high risk 
HPV types 16 and 18 and low risk HPV types 6 and 11 only are associated with 20-25% 
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of Head and neck cancers particularly oral and oropharyngeal cancers
(28)
.The most 
prevalent type in HPV-positive oral cancers is HPV type16 ( Over90%) 
(29,30,31)
. 
HPV positive cancers are clinically distinct from HPV negative cancers
(32,33,34)
. 
Oral HPV infection is transmitted sexually or perinatally. Tumors of  oropharynx 
particularly tonsillar tissue are more likely to be associated with HPV. The risk of oral 
HPV infection is linked to sexual behaviors such as oral sex, oro-genital sex and 
increased number of sexual partners. People with HPV associated cancers are younger, 
less likely to be smoker and drinkers but with different sexual behavior and marijuana use 
(32,33,34)
. 
GERD : It  is  also considered as a risk factor for laryngeal carcinoma. 
 
OTHER FACTORS : 
Factors considered in developing oral cancer and its progression includes 
ultraviolet irradiation , poor oral hygiene, immune suppression, periodontal disease 
,trauma, dental irritation , Xeroderma  pigmentosa , Fanconis anaemia, Blooms 
syndrome
(10,35)
. 
PREVENTIVE FACTORS : 
Vitamin A,C ,E are antioxidants which have protective role in oral cancer. 90% of 
oral cancer can be prevented by consumption of fruits and vegetables
(36,24)
. Iron maintains 
the thickness of the oral epithelium . Deficiency of iron causes oral atrophy leading to 
cancer in upper air and food passages. 
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Vaccines developed against HPV infection also have protective effect against oral 
and upper respiratory tract SCC. 
CLINICAL FEATURES OF ORAL AND OROPHARYNGEAL SCC : 
The patients with oral and oropharyngeal cancers are usually asymptomatic or can 
presents with vague symptoms. Patients with high risk behavior usually presents with red 
or white plaques. Advanced disease presents as proliferative growth or as nodules. The 
patients present with symptoms like referred pain to ear , difficulty in speaking 
,swallowing, bleeding  and weight loss. Such  patients can also presents with neck 
swelling (cervical lymphnodal secondaries). Advanced cases may also present with 
orocutaneous fistula.
(38)
 
CLINICAL FEATURES OF UPPER RESPIRATORY TRACT SCC: 
Like oral cavity , it  also presents as a  proliferative growth or as plaques or as 
ulcers. The symptomatology  vary according to the site. Patients can  present with  blood 
tinged postnasal drip , head ache, or as serous otitis media. But 10% of cases are 
asymptomatic. 
Glottic tumours presents as hoarseness of voice. Supraglottic tumours and 
hypopharyngeal tumours presents with voice change, neck swelling, haemoptysis and 
difficulty in swallowing. The subglottic tumours  present with difficulty in breathing and 
stridor 
(37,38)
. 
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DIAGNOSTIC PROCEDURES: 
NON INVASIVE PROCEDURES: 
Invasive procedures are always preceded by imaging modalities. MRI  is the modality of 
choice than CT  it is  superior  in assessing soft tissue infiltration, bone erosion, loco 
regional metastasis and intracranial metastasis particularly in cases of nasopharyngeal 
carcinoma 
(39,40). 
 
Other imaging modalities includes X-ray or CT – chest, bone scan, positron emission 
tomography with CT (PET-CT) and USG/CT- Abdomen for work up . 
 
INVASIVE PROCEDURES : 
            All  lesions are first proceeded with endoscopy followed by biopsy . Biopsies are 
easily taken from the grossly visible lesions. If it is not visible grossly then multiple  
biopsies are taken from suspicious sites.  
            Usually incisional biopsies are performed for all lesions but major  issue with this 
is  adequate size and  depth including lamina propria  is difficult in thick keratinising 
lesions. Punch biopsy is preferred because it gives good yield of tissue and produce 
minimal trauma 
(41).
 A proper orientation of the specimen is important otherwise it can 
exaggerate the complex architecture in the interphase between the oral epithelium and the 
lamina propria. In laser excision technique the entire potentially malignant lesion can be 
sampled. 
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Other methods : 
1) DNA CYTOMETRY(42) 
2)  EXFOLIATIVE CYTOLOGY 
3) FLUORESCENCE IMAGING 
Exfoliative cytology has high sensitivity and specificity in diagnosing premalignant 
lesions and dysplasias. Dysplasias should always be proceded with biopsy as invasion is 
not made out in exfoliative cytology. The combination of exfoliative cytology and DNA 
cytometry analysis in patients with suspicious lesion aids in diagnosing the malignancy, 
15 months prior to histological confirmation
(42,43)
. 
 
MOLECULAR PATHOGENESIS OF ORAL SQUAMOUS CELL CARCINOMA: 
                Development of oral squamous cell carcinoma involves multiple factors 
including genetic alterations and acquired causes like alcohol consumption, smoking, 
microorganisms , chemical carcinogens and ultraviolet and ionisisng radiations(36). 
Oncogenes are activated through gene amplification, augmented transcription or 
increased transforming activity due to various mutations . The inactivation of tumour 
suppressor genes occurs through various genetic changes such as mutation,  deletion , 
loss of   heterozygosity or by epigenetic alterations mainly DNA methylation or 
chromatin alteration
(36)
. 
FIELD CANCERISATION : 
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 The theory as defined by field cancerisation states that the entire oral epithelium 
is at risk of developing malignancy as a result of constant exposure to several 
carcinogenic factors and accumulation of genetic aberrations affecting the oncogenes and 
tumor suppressor genes
(44)
.
 
 
  According to this theory various oral cancers develop from independent 
cell clones. More recent studies modified this theory into the patch field carcinoma 
model (fig 1).
(45,46) 
This model states that stem cells located in the basal layer of oral 
epithelium acquires a genetic aberration which is transferred to its daughter cells. This 
patch of cells expand and cannot be seen macroscopically. In some instance it may 
present clinically as either leukoplakia or erythroplakia. 
 
Figure 1 : PATCH FIELD CANCERISATION MODEL 
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PREMALIGNANT LESIONS OF ORAL SQUAMOUS CELL CARCINOMA: 
             Premalignant lesions are defined by WHO as “A morphologically altered tissue 
in which cancer is more likely to occur than in its apparently normal counterpart”(47). 
Classification of oral potentially malignant disorders: 
Precancerous lesions: 
 Leukoplakia 
 Erythroplakia 
 Erythroleukoplakia 
Pre cancerous conditions: 
 Oral submucosal fibrosis                       
 Actinic keratosis 
 Lichen planus 
 Siderophagic dysphagia 
 Discoid lupus erythematous 
 Palatal lesions in reverse cigar smoking 
 Syphilis 
 Dyskeratosis congenital 
 Epidermolysis bullosa 
Immunosuppression 
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              Squamous mucosa of oral cavity, oropharynx and  upper aerodigestive tract  are 
subjected to various carcinogenic stimuli in the mode of chronic irritation, trauma , 
infection and carcinogenic exposure. This can present as red or white plaques called 
erythroplakia or leukoplakia   respectively.  
          A study by Mashberg and Fieldman et al, have demonstrated the transformation of 
90% cases of erythroplakia into severe dysplasia and infiltrating  squamous cell 
carcinoma (37%)
(48)
. In leukoplakia transformation into invasive squamous cell 
carcinoma is observed in 8% of cases. Thereby, erythroplakia has been demonstrated as 
having highest malignant potential. 
LEUKOPLAKIA 
The term leukoplakia was coined by Schwimmer Budapest in the year 1877 
(49)
 .  
It presents as a white plaque like lesions . More  common among smokers with higher 
predilection for floor of mouth. In non smokers it is most commonly involves lateral 
border of the tongue
(50)
 . 
 Histologically , it presents as epithelial atrophy , dyskeratosis hyperplasia with or 
without hyperkeratosis, different grades of dysplasia or carcinoma in situ
(51) 
(fig .2) 
 
 
 
  
 
Figure 2 :  HPE OF 
LEUKOPLAKIA 
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ERYTHROPLAKIA : 
It presents as a red velvety patches . Histologically it presents as atrophy or 
varying grades of dysplasias and carcinoma in situ.   
 
 
 
 
 
ERYTHROLEUKOPLAKIA : 
Erythroplakic changes developing in leukoplakic nodules are called as 
eythroleukoplakia . Associated with candidal  infection . It is associated with higher 
malignant transformation when compared to leukoplakia alone. 
 
 SQUAMOUS CELL CARCINOMA : 
According to WHO , Squamous Cell Carcinoma is defined as epithelial neoplasm 
with  varying degree of differentiation and increased  propensity for lymph nodal 
metastasis. 
WHO CLASSIFICATION  USED  
FOR   ORAL CAVITY (ANNEXURE –I ) 
FOR  OROPHARYNX  AND NASOPHARYNX (ANNEXURE II)  
FOR HYPOPHARYNX AND LARYNGEAL CARCINOMA (ANNEXURE-III) 
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HISTIOGENESIS: 
         Squamous cell carcinoma arises from  mucosa where  squamous epithelium form  
its lining and from ciliated columnar epithelium where it  undergone squamous 
metaplastic changes like in larynx
(52)
. 
Conventional squamous cell carcinoma : 
         Conventional squamous cell carcinoma can be classified into keratinizing and               
non keratinizing type . The most common is keratinizing type. 
  Depending on the keratin pearl formation , degree of differentiation it is further 
classified into  
 Well Differentiated , 
 Moderately Differentiated  And 
 Poorly Differentiated Squamous Cell Carcinoma.  
 Well Differentiated Squamous Cell Carcinoma : It has features of 
individual cell keratinisation , keratin pearl formation, mild to moderate 
hyperchroamtic pleomorphic nuclei with mild degree of mitotic activity. 
 Moderately Differentiated Squamous Cell Carcinoma : It  has  features 
of less keratinisation , distinct nuclear atypia  and  mitotic activity. 
 Poorly Differentiated Squamous Cell Carcinoma: It presents with 
marked atypia with immature cells , increased mitotic activity with  less 
features of keratinisation . 
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                 Invasiveness of squamous cell carcinoma is of either diffuse spreading  or of 
pushing type . Cells in diffuse type  spread as single cells or in cords . It has propensity 
for lymhovascular invasion . It has very less survival rate of 30-40%. 
                 Pushing type has good survival of 80-90% because it presents with less 
lymphovascular invasion .A study conducted by Crissman and Zarbo et al discussed the 
correlation of prognosis with invasive pattern
(53)
 
                Stroma shows desmoplastic reaction because of deposition of extracellular 
matrix , collagen and myofibroblast . There is foreign body reaction to keratin with 
formation of granuloma  and chronic inflammatory cell formation is also common.. 
      Dysplatic changes is common in epithelium adjacent to carcinoma. 
VARIANTS OF SQUAMOUS CELL CARCINOMA  :  
 VERRUCOUS CARCINOMA : 
          It is a well differentiated form of squamous cell carcinoma . It is otherwise called 
as ACKERMANN TUMOUR .The  most common sites are  oral cavity and larynx.  
Risk factor associated with this is tobacco smoking and HPV. 
         Macroscopically these are locally aggressive  slow growing neoplasm with warty 
exophytic lesions with pushing margins. 
          Microscopically the tumour has club shapped papillae with mature squamous cell 
proliferation .The surface of the epithelium showing church spire keratosis.The  biopsy 
sample should include stroma .Otherwise biopsy sample is considered as inadequate. It 
has very good prognosis. 
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 BASALOID SQUAMOUS CELL CARCINOMA: 
              It is a rare but most aggressive variant. Most common site is pyrifrom fossa. The 
most common  risk factor associated  is  tobacco , alcohol consumption and HPV 
infectoion . It  is presents as an ulcerated mass with induration of submucosa. 
Microscopically it is composed of both basaloid cells and squamous cells with cystic 
spaces and  comedo necrosis seen. Early recurrence and local metastasis are the features 
of  Basaloid SCC. 
 ACANTHOLYTIC SQUAMOUS CELL CARCINOMA: 
              It is a rare variant.it is more common among sun exposed areas. Most common 
site are supraglottic larynx and hypopharynx. There is no specific risk factor related to it. 
It is composed of acantholytic squamous cells with pseudo lumina formation . The main 
differential diagnosis is angiosarcoma.  The prognosis is same as that of conventional 
SCC . 
 PAPILLARY SCC :  
                 It is otherwise known as exophytic SCC. Most common site is larynx and 
hypopharynx. Grossly it presents as a polypoidal friable mass with broad base .  
Microscopically , they presents with malignant cells arranged in polypoidal pattern with 
fibrovascular core.The tumour cells are highly pleomorphic with invasion into stroma 
.The precursor lesions are papilloma and  mucosal hyperplasias. The prognosis is good. 
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 SPINDLE CELLS SCC: 
            Most common site is laynx. It is a biphasic tumour composed of both 
conventional SCC and spindle cell component invading into underlying stroma. It arises 
from epithelial  but mimicks like mesenchymal origin. The most common risk factor is 
radiation exposure. Macroscopically it presents as a polypoidal mass with thin pedicle. 
Sometime it may autoamputate and is expectorated in the sputum. Microscopically it is 
composed of biphasic population of cells with both malignant squamous cells and 
malignant spindle cells.It has poor prognosis. 
 ADENOSQUAMOUS VARIANT OF SCC : 
                   It is a high grade tumour and the most common site being larynx and 
hypopharynx. It originates from totipotent cells in the basal region. It has poor prognosis. 
It is composed of both adeno and squamous cell component with mucin positivity in the 
mucin component. 
 LYMPHOEPITHELAIL CARCINOMA : 
                  It is an undifferentiated carcinoma with extensive lymphocytic infiltrate. It 
carries poor prognosis with common site being larynx and hypophaynx. 
 GIANT CELL CARCINOMA: 
                 It is an undifferentiated carcinoma with multiple multinucleated giant cells 
with neutrophils and cell debris in its cytoplasm .It carries a poor prognosis. Common 
sites are larynx and hypopharynx. 
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STAGING : 
        Prognostic evaluation is based on TNM classification. Two well established factors 
such as  TUMOUR THICKNESS AND EXTRACAPSULAR NODAL SPREAD are 
considered as important in determining the behaviour . 
 
GRADING : 
According to WHO grading system 3 categories  are recommended 
 Well differentiated, 
 Moderately differentiated and  
 Poorly differentiated.  
        It depends on  the  subjective assessment of keratinisation, pleomorphism and 
mitotic activity. 
 BRODER’S GRADING SYSTEM(54): 
 Grade I : Well differentiated- <25% of undifferentiated cells 
 Grade II : moderatelydifferentiated -<50% of undifferentiated cells  
 Grade III : Poorly differentiated- <75% of undifferentiated cells 
  Grade IV : Anaplastic or pleomorphic->75% of undifferentiated cells  
ANNEROTH’S  GRADING :  
             It includes  the  six parameters of  which 3 are  connected to tumor population 
and other 3 are connected with tumor host relationship. The six parameters of Anneroth’s 
histological grading system included 
 Degree of keratinitization, 
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 Nuclear pleomorphism, 
 Number of mitoses, 
 Pattern of invasion,  
 Stage of invasion, 
 Lympho-plasmocytic Infiltration. 
Morphologic
al 
parameter 
Points    
 1 2 3 4 
Degree of 
keratinisation 
Highly 
keratinised (50% 
of the cells ) 
Moderately 
keratinised (20-
50%of the 
cells) 
Minimally 
keratinised (5-
20%of the cells ) 
No 
keratinisation 
(0-50%of the 
cells ) 
Nuclear 
pleomorphis
m 
Little nuclear 
pleomorphism(7
5% mature cells) 
Moderately 
abundant 
nuclear 
pleomorphism(
50-75%mature 
cells) 
Abundant 
nuclear 
pleopmorphism(
25-50% mature 
cells ) 
Extreme 
nuclear 
pleomorphism
(0-25%mature 
cells) 
No.of 
mitosis/HPF 
0-1 2-3 4-5 5 
 
The histological pattern often reflects the metastatic potential and  is correlated with the 
survival. 
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Prognostic factors : 
 Site :  
Lip is the most common site followed by anterior tongue , floor of mouth , glottis, 
supraglottis, posterior part of tongue ,sub glottis, hard palate and soft palate.
(59)
 
 Stage:  
It is the significant parameter predicting the prognosis. The recurrence-free 5-year 
survival rates  for stage I, 91.0%; stage II, 77.2%; stage III, 61.2%; stage IVA, 32.4%; 
stage IVB, 25.3%; stage IVC, 3.6%.
(56,60)
. 
 Grade:  
Grading of the deep invasive margins is more important than  grading of  the 
entire tumour in predicting the prognosis.
(55,61)
 
 Depth of invasion:  
       This is an important prognostic factor included in the staging system.
(62)
 
 Size:  
      The clinical outcome is not dependent on the size of the tumour except for the 
small sized tumour.
(63)
 
 Desmoplastic response:  
In lip carcinoma, presence of desmoplasia is a predictor of aggressive behavior.
(64)
 
 Tissue eosinophilia:  
Eosinophilic infiltration indicates a better Prognosis
(57,65)
.  
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 Lymph node involvement:  
It is a key feature in the staging system. Presence of extra capsular spread is an 
indicator of decreased survival rate.
(66)
 
 DNA ploidy:  
It correlates with tumour grade and an independent prognostic factor with 
nondiploid tumors  carrying an  unfavourable prognosis
.(67) 
 
 HPV 16:  
Presence of this is an indicator of improved survival among patients with 
oropharyngeal carcinoma
.(58)
 
P16:  
It is a surrogate marker of high risk HPV which carries a favourable Prognosis
(68)
. 
 
IMMUNOHISTOCHEMISTRY: 
Albert Coons et al in 1941 first labelled antibodies directly with Fluorescent  
isocyanate.  Nakane and Pierce et al, in 1966, introduced the indirect Labeling technique 
in which the unlabelled antibody is followed by second Antibody or substrate. Various 
stages of development of immunohistochemistry Include peroxidase – antiperoxidase 
method (1970), alkaline phosphatase Labeling (1971), avidin-biotin method (1977) and 
two layer dextrin polymer Technique  (1993). 
Immunohistochemisty involves   TWO PRINCIPLES immunology and histology. 
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IHC is used to determine the particular antigen and its subcellular location . IHC 
uses antibodies to detect antigenic differences between the cells. These differences help 
us to specifically identify the lineage of cell populations and define biologically distinct 
population of cells within the same lineage. 
The use of antiboby in IHC depends on sensitivity and specificity of antigen 
antibody reaction as well as on the hybridoma technique which provides limitless source 
of highly specific antibodies 
ANTIGEN RETRIEVAL: 
The following techniques are used for antigen retrival  
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Pressure cooker antigen retrieval 
4. Microwave and trypsin antigen retrieval 
PROTEOLYTIC ENZYME DIGESTION : 
The enzyme used is trypsin and anti proteinase. It breaks down the formalin cross 
linkages and unmask the antigen determitants. 
Disadvantages include overdigestion , underdigestion and antigen destruction . 
MICROWAVE ANTIGEN RETRIEVAL: 
 
       This is a newer technique most commonly used in current practice. Microwave oven 
heating involves boiling formalin fixed paraffin sections in various buffers for rapid and 
uniform heating.  
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PRESSURE COOKER ANTIGEN RETRIEVAL: 
            
Miller et al in 1995 compared and proved that pressure cooking method  has fewer 
inconsistencies, less time consuming and can be used to retrieve large number of slides 
than the microwave method . 
PITFALLS OF HEAT PRETREATMENT: 
        
Drying of sections at any stage after heat pretreatment destroys antigenicity. 
Nuclear details are damaged in poorly fixed tissues. Fibers and fatty tissues tend to 
detach from slides while heating. Not all antigens are retrieved by heat pretreatment and 
also some antigens like PGP 9.5 show altered staining pattern. 
DETECTION SYSTEMS: 
 
After the addition of specific antibodies to antigens, the next step is to visualize 
the antigen-antibody reaction complex. The methods employed are direct and indirect 
methods. 
In the direct method, primary antibody is directly conjugated with the  label. Most 
commonly used labels are fluorochrome, horse radish peroxidase 
and alkaline phosphatase.  
         Indirect method is a two-step method in which  labelled secondary antibody reacts 
with primary antibody bound to specific antigen. The use of peroxidase enzyme complex 
or avidin-biotin complex  further increases the sensitivity of immunohistochemical stains 
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In 1993, Pluzek et al introduced enhanced polymer one step staining, in which 
large numbers of primary antibody and peroxidase enzymes are attached to dextran 
polymer back bone. This is the rapid and sensitive method.  Dextran polymer conjugate 
two step visualization system is based on dextran technology in Epos system. This 
method has greater sensitivity and is  less time consuming. 
 
Molecular pathogenesis and genetics of  oral squamous cell 
carcinoma: 
        Oral carcinogenesis is a progressive disease  and normal epithelium passes through 
stages starting from dysplasia to finally transforming into invasive phenotypes. 
Genetic alteration in oncogenes  or tumour suppressor genes ,genomic instability 
and epigenetic modifications are involved in oral carcinogenesis. 
Several oncogenes are implicated in the oral carcinogenesis. Aberrant expression 
of EGFR, k-ras, c-myc and bcl are  involved in oral carcinogenesis. TGF- beta promotes 
neovasculariation and mitogenesis.(92)  
Several tumour suppressor genes are also involved in the carcinogenesis of oral 
scc. Among that p53 and p16 plays an important role. 
Maspin a tumour suppressor gene is involved in carcinogenesis of oral SCC . It 
acts as a main prognostic factor by preventing invasion ,angiogenesis and metastasis   
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MASPIN (MAMMARY SERINE PROTEASE INHIBITOR) : 
 It belongs to serine protease inhibitor superfamily coded by serpin b5 gene located on 
18q21.3-q23 and  was first identified in1994
(69)
. 
 It is a tumour suppressor gene and  prevents the invasion ,angiogenesis and progression 
of neoplastic cells.  
 It is expressed in skin , prostate, breast ,testis, intestine ,tongue ,lung and thymus. 
 It is down regulated in breast ,prostate , gastric carcinomas  and melanomas. 
 It is located subcellulary at cytoplasm, nucleus. It is also present in the extracellular 
region ,extracellular exosome and in extracellular spaces
(83,84,85,86 ). 
 
 
 
 
 
 
 
Figure 3: CRYSTALLOGRAPHIC PICTURE OF MASPIN 
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Basic functions(74,75)  : 
1. Morphogenesis of an epithelium  
2. Regulation of epithelial cell proliferation  
3. Extracellular matrix organization  
4. Negative regulation of endopeptidase activity  
5. Regulating the breakdown of proteins  by Inhibiting the catalytic activity of 
proteinases 
6. It also regulates phagocytosis,coagulation and fibrinolysis. 
Molecular level activity : 
Serpin  exhibits its function by conformational change from stress to relaxed state . 
RSL – reactive site loop is the key component in the serpin family(76). 
It is located in 9-15 residues amino terminal to the reactive site peptide bond. This 
allows the reactive site to present an optimal configuration for binding and inhibiting 
target protease. 
Stressed Catalytic serine residue in the protease , changes the conformation of the 
RSL loop to form an acyl  intermediate . Conformational change to the relaxed state 
levels to irreversibly trapping of the protease in an active state 
(77,78,79)
. 
Thus serpin functions as a suicide inhibitor of the protease. 
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MASPIN also act as an inhibitor of histone deacytylase. 
Its function,  as serine protease  inhibitor is down regulated  in cancers of the 
breast , prostate , stomach  and melanoma cancers  but overexpressed in  pancreatic , gall 
bladder , colorectal ,skin and thyroid cancers. 
This varying function is because of its varying subcellular localization and its  
interaction with extacellular matrix and its epigenetic  modification(70,71,72,73). 
Maspin G - alpha helix  an internal salt bridge or the p1 position of the RCL. 
It is capable of an open and closed conformational change  inducing  redistribution 
of charged residues within the molecule . 
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Effect of maspin on cell migration depends on G –alpha helix and its action on 
alpha 1 integrins
(80)
. Maspin induces the changes in the expression of protein associated 
with actin cytoskeleton that predicts a less motile and invasive phenotype and reduced 
metastatic spread
(81,82)
 . Action of maspin on cell migration is also the result of 
inactivation of beta 1 integrins sub unit. 
Tumour metastasis requires the cell detachment and invasion through the 
basement membrane and stroma. During  metastasis of tumour many genes are reduced 
or  silenced during this process. 
Maspin is also silenced during this process and promotes cell invasion , 
angiogenesis and more recently apoptosis. Maspins  role on protease inhibitor is 
considered to be supressing activity in tumour metastasis. 
Maspin is epigenetically regulated in tissue specific way. Epigenetic changes of 
maspin expression involves cytosine methylation, histone deacetylation and chromatin 
accessibility causing loss of its function .
(87,88,89) 
ROLE OF MASPIN IN HEAD AND NECK CANCER : 
Maspin represents an useful marker to identify the potential for progression of 
head and neck cancer , since lower immunoreactivity is associated with larger tumour and 
greater invasive potential . 
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 Fig 4 : Hypothetical Model Of Maspin Expression In Oral Squamous Cell 
Carcinomas 
Future perspectives : Maspin expression was found directly correlated with 
treatment including carboplatin with radiotherapy in primary head and neck squamous 
cell carcinoma.
(90)
 
Thus maspin shows a positive prognostic value. Therapeutic approaches studied so 
far aimed to reactivate a dormant tumour supressor gene by designed transcription 
factors
(91)
.  
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MATERIALS AND METHODS 
STUDY DESIGN  :  Retrospective and comparative study 
SOURCE OF DATA  :  Incisional biopsy / Excision biopsy specimen of oral cavity 
lesion was obtained from Department of Oto Rhinolaryngology and Surgery  and 
reported by Department Of Pathology ,Govt Stanely Medical College ,Chennai. 
STUDY PERIOD  : This study was  from  January 2016 to December 2016 
PILOT STUDY :  Done with 5 specimens  in September 2015 submitted to institutional 
ethical committe in  October 2016 and approval obtained . 
SAMPLE SIZE ESTIMATION : Level of expression of maspin and intensity of 
staining in malignant cells was considered as the primary variable in calculating the 
sample size . 
TOTAL SAMPLE SIZE : 88 
STUDY GROUPS : 
Group 1 : Specimen diagnosed as malignant by Histopatholgical Examinantion – Well 
Differentiated SCC  
Group 2 : Specimen diagnosed as malignant by Histopatholgical Examinantion – 
Moderately Differentiated  
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Group 3  : Specimen diagnosed as malignant by Histopatholgical Examinantion – Poorly 
Differentiated 
RANDOM SELECTION :  
             All cases were selected by simple randomisation  . Out of all specimens reported 
during  January 2016to December 2016; 36 were Well Differentiated Squamous Cell 
Carcinoma  36  were Moderately Differentiated  Squamous  Cell Carcinoma;  16 were 
Poorly Differentiated Squamous Cell Carcinoma. 
INCLUSION CRITERIA: 
All Histopathological variants of Oral Squamous Cell Carcinoma reported in 
Department Of Pathology  ,Stanley Medical College during the period of  January 2016 
to December 2016 sent from Department Of  Surgery and Otorhinolaryngology. 
EXCLUSION CRITERIA : 
1) Benign neoplasm arising from the oral mucosa will not be included in this study. 
2) Primary malignancies of oral cavity other than Squamous Cell Carcinoma will not be 
included in this study. 
3) Recurrence and Metastatic tumours of the oral cavity. 
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METHODS OF STUDY : 
Detailed history regarding the patients age ,  gender ,site , personal history were 
collected from the surgical pathology records. 
Sections of 4 micrometer thickness were taken from the corresponding paraffin 
blocks by using semi automated microtome with disposable blades and followed by 
staining with Haematoxylin and Eosin stain. The stained sections were then reviewed. 
Sections showing normal histology ,features of dysplasia and features of 
carcinoma were named accordingly. Malignant cases were further categorized into three 
grades. With or without nodal metastasis was further categorized. 
36 cases of well differentiated  , 36 cases of moderately differentiated , 16 cases of 
poorly differentiated with or without nodal metastasis were selected at random for 
staining with MASPIN immunohistochemical marker. The corresponding  paraffin blocks 
of the above selected cases were taken. Sections were  cut at 4 micrometer thickness in 
semiautomated microtome using disposable blades. Chrome alum slides were used for 
this purpose. 
Sections were subjected to antigen retrival solution using pressure cooker 
technique with  TRIS buffer solution corresponding to PH 9.0 and was  subjected to bind 
with mouse monoclonal antibody (Thermofisher ) against MASPIN. This was further 
proceeded with seconday antibody and finally diaminobenzidine substrate . The entire 
steps of this procedure is explained below. 
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IMMUNOHISTOCHEMISTRY PROCEDURE 
1. 4μ thick sections were cut from formalin fixed paraffin embedded tissue 
samples and transferred to gelatin-chrome alum coated slides. 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes x 2 changes. 
5. The sections were washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
7. Heat induced antigen retrieval was done with microwave oven in appropriate 
temperature with appropriate buffer for 20 to 25 minutes. 
8. The slides were then cooled to room temperature and washed in running tap 
water for 5 minutes. 
9. The slides were then rinsed in distilled water for 5 minutes. 
10. Wash with appropriate wash buffer (citrate buffer) for 5 minutes x 2 changes. 
11. Apply peroxidase block over the sections for 10 minutes. 
12. Wash the slides in citrate buffer for 5 minutes x 2 changes. 
13. Cover the sections with power block for 15 minutes. 
14. The sections were drained (without washing) and appropriate primary 
antibody MASPIN was applied over the sections and incubated for 30 minutes . 
15. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
16. The slides were covered with Super Enhancer for 30 minutes. 
17. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
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18. The slides were covered with SS Label for 30 minutes. 
19. Wash in citrate buffer for 5 minutes x 2 changes. 
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 1 ml of 
DAB buffer. 
21. DAB substrate solution was applied on the sections for 8 minutes. 
22. Wash with citrate buffer solution for 5 minutes x 2 changes. 
23. The slides are washed well in running tap water for 5 minutes. 
24. The sections were counterstained with Hematoxylin stain for 2 seconds 
(1 dip). 
25. The slides were washed in running tap water for 3 minutes. 
26. The slides were air dried, cleared with xylene and mounted with DPX.. 
 
ANTIGEN VENDOR SPECIES DILUTION POSITIVE 
CONTROL 
MASPIN THERMOFISHER MOUSE READY TO 
USE(NO 
DILUTION)  
Normal oral 
squamous 
epithelium 
INTERPRETATION : 
Immunohistochemical slides were labelled , viewed and analysed . The immunopostivity 
was confirmed  by the presence of brown coloured staining in the cytoplasm of the 
tumour cells. 
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Evaluation of expression of immunohistochemical expression of Maspin in tumour 
cells : 
Maspin expression  was semi quantitatively evaluated by percentage of cells positive for 
maspin staining and the intensity of maspin staining .
(93)
. 
 Percentage of positive cells was scored as follows: 
 0 point- Maspin positive in 0–5% of cells 
 1 point – Maspin positivity in 5-10% of cells 
 2 points -Maspin positive in 6–50% of cells  
 3 points- Maspin positive in more than 50% of cells 
 The staining intensity was scored as follows: 
 1 point: negative or weak staining 
 2 points: moderate staining 
 3 points: strong staining.  
 
The OVERALL MASPIN EXPRESSION (OME) was assessed based on the 
percentage  of positive cells category points and the intensity category points in each 
case.  
Tumors were categorized into four groups: 
 NEGATIVE  : < 5% of cells stained, regardless of intensity  
 WEAK EXPRESSION : OME: 0–2 points 
 MODERATE EXPRESSION : OME: 3–4 points 
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 STRONG EXPRESSION : OME: 5–6 points 
 PARAMETERS STUDIED : 
The following parametes were evaluated : 
1. Age  
2. Gender  
3. Site 
4. Histopathology report 
5. Overall Maspin Expression (OME) 
Results were tabulated accordingly and analysed. 
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STATISTICAL ANALYSIS 
             Totally   9374 cases were reported in the Govt Stanley Medical College during 
the period of January 2016 to December 2016 .  246 cases were taken from the oral cavity 
. Out of which 153 cases were reported as malignant. Among malignant cases  88 cases 
were randomly selected . 
          OVERALL MASPIN EXPRESSION (OME) is considered as the primary outcome 
variable. Various histological grades of tumours and nodal status are considered as the 
explanatory variables. The sociodemographic variables like age , gender, were considered 
as other explanatory variables 
           Descriptive analysis: Descriptive analysis was carried out by mean and standard  
deviation for quantitative variables, frequency, and proportion for categorical variables. 
Data was also represented using appropriate diagrams like bar diagram, pie diagram, and 
box plots. 
INFERENTIAL STATISTICS: 
Quantitative outcome;  
         The association between categorical explanatory variables and the quantitative 
outcome was assessed by comparing the mean values. The mean differences along with 
their 95% CI were presented. Independent sample t-test was used to assess statistical 
significance. 
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        Categorical outcome: 
            The association between explanatory variables and categorical outcomes was 
assessed by cross tabulation and comparison of percentages. Chi square test was used to 
test statistical significance. 
P value < 0.05 was considered statistically significant. IBM SPSS version 22 was 
used for statistical analysis 
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OBSERVATION AND RESULTS: 
A total of 88 subjects were included in the analysis. 
 
Table 1: Descriptive analysis for AGE in study population (N=88) 
 
Parameter Mean ± STD Median Min Max 
95% C.I. for EXP(B) 
Lower Upper 
AGE 53.55 ± 10.09 55.00 32.00 75.00 51.42 55.70 
The mean age of study population was 53.55 with minimum age being  32 years and 
maximum being 75 years in this  study population (95% CI 51.42- 55.70). 
---Figure 1:  Box and whisker plots of AGE in the study population(N=88) 
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Table 2: Descriptive analysis of GENDER in study population (N=88) 
 
 
Among the study population, number of males 73(82.95%) was higher than females 
15(17.05%). (table 2) 
Figure 2: Bar chart of GENDER distribution in study population (N=88) 
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GENDER Frequency Percentage 
MALE 73 82.95% 
FEMALE 15 17.05% 
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Table 3: Descriptive analysis of SITE in study population (N=88) 
 
Parameter Frequency Percentage 
BUCCAL MUCOSA 21 23.86% 
VOCAL CORD 10 11.4% 
TONGUE ANTERIOR 2/3 19 21.59% 
HYPO PHARYNX 9 10.23% 
TONGUE POSTERIOR 1/3 9 10.23% 
LIP 6 6.82% 
RETROMOLAR TRIGONE 4 4.55% 
OROPHARYNX 3 3.41% 
SUPRAGLOTTIS 2 2.3% 
GLOTTIS 2 2.3% 
HARD PLATE 1 1.14% 
PYRIFORM FOSSA 1 1.13% 
EPIGLOTTIS 1 1.13% 
Among the study population, the most common site of involvement was buccal 
mucosa in 21 (23.86%) subjects. It was followed by anterior two third of tongue 
19(21.59%), vocal cord in 10(11.4%) , hypo pharynx and  posterior one third tongue  in 9 
(10.23%) subjects each. The summary of other sites involved is presented in table 3. 
(Table 3) 
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Figure 3: Bar chart of SITE distribution in study population (N=88) 
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Table 4: Descriptive analysis of Tumour stage and Nodal status  in study population 
(N=88) 
Parameter Frequency Percentages 
I.T 
T1 43 48.86% 
T2 39 44.32% 
T3 6 6.82% 
II.N 
N0 56 63.64% 
N1 15 17.05% 
N1 A 3 3.41% 
N1 b 1 1.14% 
N2 3 3.41% 
N2 a 2 2.27% 
N2 b 7 7.95% 
N3 1 1.13% 
Among the study population, as per the TNM staging, majority of the study 
population were in T1 (48.86%). The number of subjects in T2 and T3 were 39(44.32%), 
and 6(6.82%) respectively. The proportion of subjects with no nodal involvement was 
63.64% in study population. The proportion of subjects in N1, N1 A and N1b  categories 
were 17.05%, 3.41% and 1.14% respectively. The proportion of subjects in N2, N2a and 
N2b categories were 3.14%, 2.27% and 7.95% respectively. Only 1 (1.135) subject was 
in N3 category. (Table 4)   
 
 
 
51 
 
Table 5: Descriptive analysis of nodal metastasis in study population (N=88) 
 
N Frequency Percentages 
Nodal metastasis present 32 36.36% 
Nodal metastasis absent 56 63.64% 
 
Among the study population, the proportion of subjects with any nodal metastasis was 
36.36%. (Table 5) 
 
Fig4: Pie chart of N distribution in study group (N=88) 
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Table 6: Descriptive analysis of Grade in study population (N=88) 
 
Among the study population, the tumor was Grade I in 36 (40.91%), Grade II in 
36 (40.91%) and Grade III in 16(18.18%) subjects. (Table 6) 
 
Figure 5: Pie chart of Grade distribution in study population (N=88) 
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Table7 : Descriptive analysis of Stage in study population (N=88) 
 
STAGE Frequency Percentages 
I 32 36.36% 
II 22 25.00% 
III 21 23.86% 
IVA 12 13.64% 
IV B 1 1.14% 
Among the study population. The staging of tumor was Stage I in 32(36.36%), 
Stage II in 22(25.00%), Stage III in 21(23.08%) people. Stage IVA and Stage IV B tumor 
was present in 12(13.64%)and 1(1.14%) subject respectively. (Table 7) 
Fig6: Pie chart of STAGE distribution in study group (N=88) 
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Table8: Descriptive analysis of intensity of Expression in study population (N=88) 
 
Among the study populationIntensity of Expression was Negativein 28(31.82%) 
people. The intensity expression was Weak in 13(14.77%), Moderate in 24(27.27%) and 
Strong in 23(26.14%) subjects. (Table 8) 
Figure 7: Bar chart of intensity of Expression distribution in study population 
(N=88) 
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Negative
Weak
Moderate
Strong
Intensity of Expression Frequency Percentage 
Negative 28 31.82% 
Weak 13 14.77% 
Moderate 24 27.27% 
Strong 23 26.14% 
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Table9: Descriptive analysis for LENGTH, WIDTH, HEIGHT, TOTAL AREA in 
study population (N=88) 
          The Mean total area of study population was  8.291 with minimum 0.38 and 
maximum 15.75 area in the study population(95%CI-10.83-27.41). 
Table10: Descriptive analysis of score for NUMBER OF CELLS STAINED AND 
INTENSITY OF STAINING  in study population(N=88) 
 
Parameter Mean±STD Median Min Max 
95% C.I. for EXP(B) 
Lower Upper 
LENGTH 3.066±1.401 3.50 1.50 4.20 -0.41 6.55 
WIDTH 1.833±1.154 2.50 0.50 2.50 -1.04 4.70 
HEIGHT 1.166±0.577 1.50 0.50 1.50 -0.27 2.60 
TOTAL AREA 8.291±7.697 8.75 0.38 15.75 -10.83 27.41 
Parameter Frequency Percent 
I.NUMBER OF CELLS STAINED 
0 29 32.95% 
1 12 13.64% 
2 26 29.55% 
3 21 23.86% 
II.INTENSITY OF STAINING 
0 12 13.64% 
1 31 35.23% 
2 30 34.09% 
3 15 17.05% 
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Among the study population, number of cells stained was scored as 0,1,2and 3 
according to the numbe of cells stained . The score was 0,1,2 and 3  respectively in 
29(32.95%),12(13.64%), 26(29.55%) and 21(23.865)cases .The intensity of staining was 
also graded 0,1,2 and 3 which is  12(13.64%), 31(35.23%), 30(34.09%), and 15 (17.05%) 
subjects respectively. (Table 10)   
Table11: Association of OVERALL MASPIN EXPRESSION (OME) with GRADE 
of study population (N=88) 
GRADE 
OVERALL MASPIN EXPRESSION (OME) 
Chi 
square 
P-
value 
Negative Weak Moderate Strong 
I 7 (19.44%) 5 (13.88%) 6 (16.66%) 18 (50%) 
29.73 <0.001 II 10 (27.77%) 5 (13.88%) 16 (44.44%) 
5 
(13.88%) 
III 11 (68.75%) 3 (18.75%) 2 (12.5%) 0 (0%) 
Among grade I subjects, the proportion of subjects with Overall Maspin 
Expression (OME)  Expression Negative was   7 (19.44%), Weak was 5 (13.88%), 
Moderate was 6 (16.66%) and strong was 18 (50%).The proportion of subjects with 
OVERALL MASPIN EXPRESSION (OME)  Expression  Negative was   10 (27.77%), 
Weak was 5 (13.88%), Moderate was 16 (44.44%) and strong was 5 (13.88%)in subjects 
with Grade II. The proportion of subjects with Overall Maspin Expression (OME) 
Expression  Negative was   11 (68.75%), Weak was 3 (18.75%), Moderate was 2 (12.5%) 
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and strong was 0 (0%) in subjects with GradeIII.The differences in proportion Across the   
groups was statistically significant (P value<0.001). (Table 11). 
Fig 8: Bar chart of OVERALL MASPIN EXPRESSION (OME) Expression between 
Grade distribution in study group (N=88) 
 
 
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1 2 3
O
M
E 
GRADE 
STRONG
MODERATE
WEAK
NEGATIVE
GRADE
 
 
 
58 
 
Table 12: Association of OVERALL MASPIN EXPRESSION (OME) Expression 
with N of study population (N=88) 
 
N 
OVERALL MASPIN EXPRESSION (OME)  
 
Chi 
square 
P-value 
Negative Weak Moderate Strong 
Nodal 
metastasis 
present 
24 (75%) 7(21.87%) 1 (3.125%) 0 (0%) 
55.08 <0.001 
Nodal 
metastasis 
Absent 
4 (7.142%) 6(10.71%) 23 (41.07%) 23(41.07%) 
 
Among people with nodal metastasis, the proportion of subjects with OVERALL 
MASPIN EXPRESSION (OME) Negative was   24 (75%), Weak was 7 (21.87%), 
Moderate was 1 (3.125%) and Strong was 0 (0%). In people without nodal metastasis, the 
proportion of subjects with Overall Maspin Expression (OME)  Negative was   4 
(7.142%), Weak was6(10.71%), Moderate was 23 (41.07%)and Strong was 
23(41.07%)The differences in proportion between the two groups was statistically 
significant (P  value<0.001). (Table 13). 
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Fig 9: Bar chart of OVERALL MASPIN EXPRESSION (OME) between N 
distribution in study group (N=88) 
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Table 13: Association of OVERALL MASPIN EXPRESSION (OME) with STAGE 
of study population (N=88) 
 
STAGE 
OVERALL MASPIN EXPRESSION (OME)  
Chi 
square 
P-value 
Negative Weak Moderate Strong 
I 0 (0%) 3(9.375%) 11 (34.37%) 18(56.25%) 
68.07 <0.001 
II 3 (13.63%) 3(13.63%) 11 (50%) 5 (22.72%) 
III 13 (61.90%) 6(28.57%) 2 (9.523%) 0 (0%) 
IV B 1 (100%) 0 (0%) 0 (0%) 0 (0%) 
IVA 11 (91.66%) 1(8.333%) 0 (0%) 0 (0%) 
 
Among Stage I subjects, the proportion of subjects with OVERALL MASPIN 
Expression was Negative in   0 cases  (0%), Weak in  3(9.375%), Moderate in  11 
(34.37%) and was  strong in  18(56. 25%).The proportion of subjects with Expression  
Negative was   3 (13.63%), Weak was 3(13.63%), 
Moderate expression was seen in 11 (50%)and strong expression  was seen in  5 
(22.72%)  subjects with Stage II. The proportion of subjects with Overall Maspin 
Expression was negative in  13 (61.90%), Weak in 6(28.57%), Moderate in 2 (9.523%) 
and strong in 0 (0%) of  subjects with Stage III. The proportion of subjects with Overall 
Maspin Expression was negative in 1 (100%), Weak in 0 (0%), Moderate in 0 (0%) and 
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strong in  0 (0%) of  subjects with Stage IVB.The proportion of subjects with Expression 
was negative in 11 (91.66%)Weak in 1(8.333%), Moderate in 0 (0%)  and strong in 0 
(0%) subjects with Stage IVA.The differences in proportion across the   groups was 
statistically significant (P value<0.001). (Table 14). 
Fig 10: Bar chart of  OVERALL MASPIN EXPRESSION (OME) between Stage 
distribution in study group (N=88) 
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Table 14: Association of INTENSITY OF STAINING with GRADE of study 
population (N=88) 
 
GRADE 
INTENSITY OF STAINING 
Chi 
square 
P -
value 
0 1 2 3 
I 3 (8.333%) 8(22.22%) 15(41.66%) 10(27.77%) 
26.107 <0.001 II 2 (5.555%) 15(41.66%) 14(38.88%) 5 (13.88%) 
III 7 (43.75%) 8 (50%) 1 (6.25%) 0 (0%) 
 
Among grade I subjects, the proportion of subjects with intensity of staining 0 was 
3 (3 (8.333%), 1 was 8 (22.22%), 2 was 15 (41.66%) and 3 was 10 (27. 77%).The 
proportion of subjects with intensity of staining 0 was 2 (5.555%), 1 was 15(41.66%),2 
was 14(38.88%)and 3 was 5 (13.88%)in subjects with Grade II. The proportion of 
subjects with intensity of staining0 was7 (43.75%), 1 was 8 (50%), 2 was 1 (6.25%)and 3 
was 0 (0%)in subjects with GradeIII.The differences in proportion Across the   groups 
was statistically significant (P value<0.001). (Table 15). 
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Fig 11: Bar chart of INTENSITY OF STAINING between grade distribution in 
study group (N=88)
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Table 15: Association of INTENSITY OF STAINING with N of study population 
(N=88) 
 
N 
INTENSITY OF STAINING 
Chi 
square 
P-
value 
0 1 2 3 
Nodal 
metastasis 
present 
10 (31.25%) 17(53.12%) 4 (12.5%) 1(3.125%) 
28.60 <0.001 
Nodal 
metastasis 
absent 
2 (3.571%) 14 (25%) 26(46.42%) 14 (25%) 
 
Among people with nodal metastasis, the proportion of subjects with intensity of 
staining 0 was   10 (31.25%), 1 was 17(53.12%),2 was 4 (12.5%)and 3 was 1(3.125%). In 
people without nodal metastasis, the proportion of subjects with intensity of staining 
0was   2 (3.571%), 1 was 14 (25%), 2 was 26(46.42%)and 3was 14 (25%).The 
differences in proportion between the two groups was statistically significant (P 
value<0.001).(Table 16). 
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Fig 12: Bar chart of INTENSITY OF STAINING between N distribution in study 
group (N=88) 
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Table 16: Association of INTENSITY OF STAINING with STAGE of study 
population (N=88) 
 
STAGE 
INTENSITYOF STAINING 
 Chi 
square 
P-
value 
0 1 2 3 
I 0 (0%) 9 (28.12%) 12 (37.5%) 11(34.37%) 
61.30 <0.001 
II 1 (4.545%) 5 (22.72%) 13(59.09%) 3 (13.63%) 
III 3 (14.28%) 13(61.90%) 5 (23.80%) 0 (0%) 
IVA 8 (66.66%) 4 (33.33%) 0 (0%) 0 (0%) 
IV B 0 (0%) 0 (0%) 0 (0%) 1 (100%) 
Among Stage I subjects, the proportion of subjects with intensity of staining 0 was 
  0 (0%), 1 was 9 (28.12%), 2 was 12 (37.5%)and 3 was 11(34.37%). The proportion of 
subjects with intensity of staining 0 was 1 (4.545%), 1 was 5 (22.72%), 2 was 
13(59.09%)and 3 was 3 (13.63%)in subjects with Stage II. The proportion of subjects 
with intensity of staining 0 was 3 (14.28%), 1 was 13(61.90%), 2 was 5 (23.80%) and 3 
was 0 (0%) in subjects with Stage III. The proportion of subjects with intensity of 
staining 0 was 8 (66.66%), 1 was 4 (33.33%), 2 was 0 (0%) and 3 was 0 (0%) in subjects 
with Stage IVA.The proportion of subjects with intensity of staining 0 was 0 (0%)1was 0 
(0%) ,2 was 0 (0%) and3was 1 (100%)in subjects with Stage IVB. The differences in 
proportion across the   groups was statistically significant (P value<0.001). (Table 16). 
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COLOUR PLATES 
 
FIGURE 5:  SQUAMOUS CELL CARCINOMA– LATERAL BORDER OF TONGUE 
 
 
FIGURE 6 : SQUAMOUS CELL CARCINOMA – GLOTTIS 
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FIGURE 7 : CONTROL – NORMAL SQUAMOUS EPITHELIUM 
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FIGURE 8 :WELL DIFFERENTIATED SQUAMOUS CELL CARCINOMA 
 
FIGURE 9 :WELL DIFFERENTIATED SQUAMOUS CELL CARCINOMA SHOWS 
STRONG POSITIVITY OF MASPIN 
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FIGURE 10 : MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA 
 
FIGURE 11 : MODERATELY DIFFERENTIATED SQUMAOUS CELL CARCINOMA – 
MASPIN SHOWING MODERATE EXPRESSION WITH STRONG POSITIVITY OF 
NORMAL SQUMAOUS EPITHELIUM ( INTERNAL CONTROL ) 
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FIGURE 12 : POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA 
 
FIGURE 13 :POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA  SHOWING   
NEGATIVE STAINING  FOR MASPIN 
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FIGURE 14 : LYMPH NODE SHOWING SQUAMOUS CELL CARCINOMA DEPOSITS 
 
FIGURE 15 : WELL DIFFERENTIATED SQUAMOUS CELL CARCINOMA WITH NODAL 
METASTASIS  SHOWING WEAK EXPRESSION OF MASPIN 
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FIGURE 16 : MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA  
WITH ABSENT NODAL METASTASIS SHOWING  STRONG POSITIVITY FOR MASPIN 
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DISCUSSION 
In  Head  and Neck Tumours , Squamous Cell Carcinoma remains the most 
common malignancy and  it  ranks 6
th
 among  the most common malignancy world wide. 
In India the incidence of oral SCC is 30-50% of all malignancies. It is the 
commonest malignancy which has great impact not only on survival but also on the  
quality of life. Oral SCC has high potential for  invasion into local tissues and also 
presents with high incidence of   lymph nodal  metastasis. 
These malignancies are usually diagnosed at advanced stage and the expected 5 
year  survival rate falls to 10-40%. This poor survival rate is due to persistent 
uncontrollable disease and poor  understanding at the molecular level. 
Tumour  metastasis is a multistep process includes local invasion , angiogenesis , 
disruption of adhesion to neighbouring cells and the extracellular matrix adhesion  and  
transgression of endothelial cells to access  into and out of the vascular circulation , 
attachment and  proliferation  at distant sites. 
Maspin  inhibits  motility  and  cell invasiveness .It is considered that maspin is 
involved in inhibiting  the initial step in the metastasis of oral squamous cell carcinoma. 
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 This study aims at understanding the neoplastic transformation , progression and 
metastasis at molecular level . So novel therapeutic medication could be designed for 
treating head and neck  squamous cell carcinoma. 
            In the current study , clinicopathological  and immunohistochemical evaluation 
was done in  88 cases of  SCC. An attempt was made to assess the significance of maspin 
expression and its correlation with prognosis , so that targeted therapy can be tried for 
better prognosis. 
The total number of specimens received in Govt.Stanley Medical College  from  
January 2016 to December 2016 was  9374  out of which 246  from oral cavity among 
that 153 cases  were malignant. 
 AGE DISTRIBUTION OF OSCC:  
This study showed that incidence of OSCC is from 3
th
 to 7 th decade . The highest 
incidence was noted in 5
th
 decade of life . The mean age of presentation was  55 . Other 
study Samina zaheer et al showed that mean age of presentation is 56.84 with a range 
falling between  5
th
 to 6
th
 decade. 
 Samina zaheer et al  Current study 
Mean age of presentation  56.84 53.55 
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SEX DISTRIBUTION : 
Current study showed a male predominance of 82.95% compared with females which  
was about  17.05%. Comparative study of Samina zaheer et also showed an  increased 
incidence among males than females. 
SITE DISTRIBUTION: 
In the current study the most common site was  tongue with 39.59%  followed by buccal 
mucosa  and lip . In  the  study  conducted by Samina Zaheer et al the  incidence 
accounted to 32%  in the  tongue  ,followed by  22% in the lip and 20% in the  buccal 
mucosa.This was in accordance to the present study  
Another study conducted by Yoshizawa et al showed that the common site was tongue 
accounting to  34%, lip being 20 % and  buccal  mucosa  being 8%. 
Comparision of distribution of oral SCC with other study groups :   
Tumour site  Samina Zaheer et 
al  
Yoshizawa et al Current study 
Tongue  32% 34% 39.59% 
Buccal mucosa  20% 8% 23.88% 
Lip 22% 20% 6.82% 
   In our study population , out of 88 cases , 36 cases were reported as well differentiated 
squamous cell carcinoma(fig 8), 36 cases were reported as moderately differentiated 
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squamous cell carcinoma(fig 10) and the remaining 16 cases were reported as poorly 
differentiated squamous cell carcinoma(12). When compared with other studies ,the 
following were the observation . 
Histological grade of 
differentiation 
Samina zaheer et 
al 
Yoshizawa et 
al 
Current 
study 
Well differentiated 29 44 36(40.91 %) 
Moderately differentiated 12 16 36 (40.91%) 
Poorly differentiated 9 11 16 (18.18%) 
WHO has classified the Squamous Cell Carcinoma into three grades based on the 
histopathological features, which includes both architectural and cytological criteria . In 
our study,both well differentiated and moderately differentiated SCC were reported in 
equal  propotion .This was not in concurrence with other studies where  well 
differentiated carcinoma was the most common type.   
NODAL STATUS : 
Nodal status Xia et al Yoshizawa et al Current study 
 Nodal Metastasis Present  10 41 32(36.36 %) 
Absent nodal metastasis  34 30 56(63.64 %) 
In our study population out of 88 cases 56 (63.64 %) cases presented without 
nodal metastasis and  remaining  32 cases presented  with nodal metastasis. This was 
found going hand  in hand with  Xia et al where most cases  were nodal negative.   
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TUMOUR STAGING : 
Tumour staging Yoshizawa et al Current study 
T1 19 43 
T2 31 39 
T3 6 6 
T4 15 0 
In our study population out of 88 cases , 43 cases   presented at T1 stage ,39 cases 
were of T2 stage , 6 cases were of T3 and  none of the cases  presented in T4 stage. Thus 
in  our study  majority of cases were of T1 stage. This was not in concurrence with other 
study were T2 was the most common stage of presentation.   
ASSOCIATION OF OVERALL  MASPIN EXPRESSION AND HISTOLOGICAL 
GRADING OF TUMOUR : 
Histological grade 
Samina Zaheer et 
al 
Yoshizawa et 
al 
Current 
study 
Well differentiated SCC 22 31 29 
Moderately differentiated 
SCC 
10 10 26 
Poorly differentiated SCC 3 5 5 
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The  overall maspin expression  in any form such as strong , moderate and weak 
was taken as positive and such  positivity was documented  in 29 cases of  well 
differentiated SCC, 26 cases of  moderately differentiated SCC and 5 cases of  poorly 
differentiated SCC in our study population.Thus it was observed that ,well differentiated 
carcinoma shows increased expression of maspin than pooly differentiated carcinoma . 
This was going hand in hand with Samina Zaheer et al andYyoshizawa et al. It shows 
statistically significant outcome with p value of 0.001 ( table : 11)  
COMPARISION OF ASSOCIATION OF  OVERALL MASPIN EXPRESSION AND 
TUMOUR STAGING WITH OTHER STUDIES : 
TUMOUR STAGING YOSHIZAWA ET AL CURRENT STUDY 
I 100% 70.25% 
II 100% 75.72% 
III 80% 38.093% 
IVA 66.7%% 8.333% 
IV B 10% 0% 
In our study population , overall Maspin expression was highest in stage I and 
stage II tumours . as stage progesses the expressionwas found to be  decreased. This was 
in concurrence with Yoshizawa et al where the expression were reduced as the stage 
progresses.This shows a statistically significant outcome with p value of <0.001  
(table 13). 
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COMPARISION OF OVERALL MASPIN EXPRESSION (OME) IN TUMOUR 
PRESENTS WITH LYMPHNODAL METASTASIS : 
OVERALL MASPIN 
EXPRESION(OME) 
XIA ET 
AL 
YOSHIZAWA ET 
AL 
CURRENT 
STUDY 
POSITIVE 0 18(43.9%) 8(25%) 
NEGATIVE 10 23(56.1%) 24(75%) 
In our study population out 88 cases , 32 cases presented with nodal metastasis. 
The overall Maspin expression was positive in 25 % of cases and 75 % of cases shows 
negative Maspin expression. This was in concurrence with yoshizawa et al  were 56.1 % 
cases shows negative Maspin expression  and xia et al shows 100 % negative staining.    
COMPARISION OVERALL MASPIN EXPRESSION(OME) IN TUMOUR WITH 
ABSENT LYMPHNODAL METASTASIS : 
OVEALL MASPIN 
EXPESSION(OME) 
XIA ET 
AL 
YOSHIZAWAET 
AL 
CURRENT 
STUDY 
POSITIVE  15 2(6.7%) 4(7.142%) 
NEGATIVE 19 28(93.3%) 52(92.58%) 
In our study population out of 88 cases,56  cases presented without  nodal 
metastasis. The overall Maspin expression was positive only in 4 cases (7.142 %) and 52 
cases(92.58 %)  showed  negative Maspin expression. This was in concurrence with the 
study conducted by Yoshizawa et al  which showed  negative Maspin expression in  93.3 
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% cases. This showed a  statistically significant out come with p value  of  < 0.001 in this 
study. The p value of our study is compared with other studies in the following table. 
COMPARISION OF P VALUES  WITH OTHER STUDY GROUPS: 
STUDY GROUPS PVALUES 
XIA ET AL 0.009 
YOSHIZAWA ET AL <0.0001 
CURRENT STUDY <0.001 
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SUMMARY 
 This study  was a retrospective and comparative study conducted in the 
Department Of Pathology, Govt .Stanley Medical College during the period of 
January 2016 to December 2016. 
 The total number of specimens received in Govt.Stanley Medical College were 
9374 out of which 246 were from oral cavity and upper respiratory tract. 
 153 cases  were documented as malignant out of the 9374 cases. 
 Most common age group of occurrence of  OSCC was noted in the 5th decade with 
mean age of presentation at 53.55yrs. 
 Males were commonly affected by  OSCC with an  incidence of 82.95% than 
females which accounted to  17.05%. 
 Tongue was  the  most common site for oral SCC accounting to  39.59%  followed 
by  buccal mucosa  accounting to  23.86 %. 
 In this study we noted  that Well differentiated SCC (36 cases )and Moderately 
differentiated SCC ( 36 cases)  were reported in equal proportion and Poorly 
differentiated SCC in 16 cases. 
 In this study 36.36% of cases presented with nodal metastasis and 63.64% of cases 
presented without nodal metastasis. 
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 In our study  Oral SCC  presented predominantly as  stage I with an incidence of 
36.36%. 
 Among Well Differentiated SCC , Maspin was strongly expressed in 50% of cases 
and weakly expressed in 19.44% of cases .The intensity of staining  score was 
 score 3 in 27.7% of cases and score 0 in 8.33% of cases. 
 In Moderately Differentiated SCC ,  Maspin was strongly expressed in 13.88%  of 
cases and was negative in 27.77% of cases. The intensity of staining score was 
score 3 in 13.88 % of cases and score 0 in 5.555% of cases. 
 In Poorly Differentiated SCC, none of the cases  showed strong expression  and 
 18.75 % of cases showed weak expression  while  68.75 % of cases showed  
negative    expression.The  intensity of staining score 3 was not seen in any  of the 
cases , score 1 was  in 50 % of cases  and score 0 in 43.75%.cases.. 
 Cases with absent nodal metastasis showed  strong maspin expression accounting 
to 41.07 %  and negative in 7.142 %. 
 None of the Cases with nodal metastasis  showed strong maspin expression  while 
 75 % of cases showed  negative expression . 
 Thus in this study the overall maspin expression was highest  in well differentiated 
squamous cell carcinoma and lowest in poorly differentiated squamous cell 
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carcinoma.Overall maspin expression was highest in nodal negative  cases than 
nodal positive cases. Nodal positive cases showed a deceased maspin expression. 
 Thus Maspin is considered as a  prognostic marker, where loss of its expression 
indicates a bad prognosis  with increased incidence of  metastatic potential of such  
tumours  . 
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CONCLUSION 
This study showed the increased prevalence of Oral  SCC among the general 
population . 
Because of its aggressive nature , invasiveness  and metastatic potential and its 
increasing trend in younger individuals , it is necessary to understand the carcinogenesis 
at molecular level. 
In this study we attempted to evaluate the correlation between Maspin expression 
and various prognostic factors such as stage and grades of tumours . This study also 
evaluates the level of maspin expression in  tumours  presented with and without nodal 
metastasis. 
This study showed  a statistically significant association in the form of inverse 
correlation between the subcellular localization, histological grades ,stages  of  tumour 
and also with lymphnodal status. 
However  because of non availability of patient follow up details and outcome, the 
current study does not provide the idea about the Maspin expression with patient outcome 
and treatment effect. 
Thus in future maspin can be consider as a prognostic  marker for early diagnosis 
of  metastasis  and its  potential for progression of the tumor. Since it is a prognostic 
marker it can be considered for  targeted therapy for a better survival and outcome of the 
patients with SCC. 
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58 2850/16 70 F ORAL CAVITY 2X1 0.5 T2 N0 G-II II 2+2 MODERATE 
59 2853/16 60 M LARYNX 1.5X1 0.5 T1 N0 G-II I 2+2 MODERATE 
60 2928/16 47 M HYPO 
PHARYNX 
1.5X1 0.5 T1 N0 G-I I 3+3 STRONG 
61 3949/16 55 M BUCCAL 
MUCOSA 
1.5X1 0.5 T1 N2b G-III IVA 0+O NEGATIVE 
62 3048/16 41 F TONGUE 2.5X2 2 T2 N0 G-I II 0+2 NEGATIVE 
 
 
 
S 
NO 
BIOPSY 
NO 
AGE SEX SITE SIZE DEPTH T N GRADE STAGE 
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CELLS 
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OF 
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LEVEL OF 
EXPRESSION 
ANTERIOR 2/3 
63 3566/15 45 M TONGUE 
ANTERIOR 2/3 
2.5X2 1 T2 N1 G-I III 0+2 NEGATIVE 
64 2920/16 55 M CHEEK 2X1 0.5 T1 N0 G-I I 3+3 STRONG 
65 2443/16 68 M HARD PALATE 3.5x2 1 T2 N1 G-I III 1+1 WEAK 
66 2411/16 56 M TONGUE 
ANTERIO 2/3 
1.2x0.5 0.5 T1 N0 G-I I 3+2 STRONG 
67 3828/15 50 F CHEEK 2x1 1 T1 N0 G-I I 3+3 STRONG 
68 776/16 54 M BUCCAL 
MUCOSA 
4x3.5 1 T2 NO G-I II 2+2 MODERATE 
69 2357/15 53 M  BUCCAL 
MUCOSA 
1x1 0.5 T1 NI G-I III 1+1 WEAK 
70 6434/15 40 M  BUCCAL 
MUCOSA 
2.7x1 0.5 T2 N2B G-I IVA 0+0 NEGATIVE 
71 3471/16 40 F TONGUE 
ANTERIOR2/3 
(4) 
3x2 1 T2 N0 G-I II 1+1 WEAK 
72 6389/15 70 M RETRO MOLAR 
TRIGONE (12) 
2x2 1 T1 N0 G1 I 3+2 STRONG 
73 2671/15 47 M POSTERIOR 1/3 
TONGUE 
2.5x1 0.5 T2 N1A G1 III 0+1 NEGATIVE 
74 2850/16 70 F BUCCOL 
MUCOSA 
1x1 0.5 T1 N2 G1 IVA 0+0 NEGATIVE 
75 3809/15 65 F TONGUE 
ANTERIOR 2/3 
0.75x0.75 0.5 T1 N0 G-II I 3+3 MODERATE 
76 4099/15 65 M POST 1/3 
TONGUE 
1x0.5 0.5 T1 N0 G-II I 3+3 STRONG 
77 6528/15 35 M BUCCAL 
MUCOSA 
3.5x2 1 T2 N0 G-II II 2+2 MODERATE 
78 6435/15 72 M RIGHT BUCCAL 
MUCOSA 
3x2 1 T2 NO G-II II 2+2 MODERATE 
79 3785/15 32 M ANTERIOR 
2/3TONGUE 
1x1 0.5 T1 N0 G-II I 3+2 STRONG 
80 2231/15 55 M BUCCAL 
MUCOSA 
4.5x3 1.5 T3 N1A G-II III 0+0 NEGATIVE 
81 991/15 
A 
55 M ANTERIOR 
2/3RDTONGUE 
3x3 1.2 T2 N1A G-II III 0+2 NEGATIVE 
82 3466 A 60 M PYRIFORM 
FOSSA 
GROWTH 
1x0.5  
0.3 
T1 N0 G-II I 2+1 MODERATE 
83 3466         
B 
60 M POSTERIOR 1/3 
TONGUE 
GROWTH 
1x0.75 03 T1 N0 G-II I 1+1 WEAK 
84 5871/15 63 M TONGUE 3x1.2 0.75 T2 N0 G III II 0+0 NEGATIVEE 
85 2160/15 60 F LIP 3.3x2 1 T2 N1 G III III 0+0 NEAGTIVE 
86 2191/16 35 M RETROMOLAR 
TRIGONE 
4.2x2 1 T3 N0 G III III 0+0 NEAGTIVE 
87 1320/16 60 M VOCAL CORD  1x1 0.75 T1 N0 G III I 1+1 WEAK 
88 2494/16 55 M OROPHARYNX 0.75x0.5 0.5 T1 N0 G III I 0+0 NEGATIVE 
  
 
 
 
.ANNEXURE – I 
 
WHO CLASSIFICATION OF TUMOURS OF THE  ORAL CAVITY AND 
OROPHARYNX 
 
 
Malignant epithelial tumours 
Squamous cell carcinoma 
Verrucous carcinoma 
Basaloid squamous cell 
carcinoma 
Papillary squamous cell 
carcinoma 
Spindle cell carcinoma 
Acantholytic squamous cell 
carcinoma 
Adenosquamous carcinoma 
Carcinoma cuniculatum 
Lymphoepithelial carcinoma 
Epithelial precursor lesions 
Benign epithelial tumours 
Papillomas 
Squamous cell papilloma and 
verruca vulgaris 
Condyloma acuminatum 
Focal epithelial hyperplasia 
Granular cell tumour 
Keratoacanthoma 
Salivary gland tumours 
Salivary gland carcinomas 
Acinic cell carcinoma 
Mucoepidermoid carcinoma 
 
Adenoid cystic carcinoma 
Polymorphous low-grade 
adenocarcinoma 
Basal cell adenocarcinoma 
Epithelial-myoepithelial 
carcinoma 
Clear cell carcinoma, not 
otherwise specified 
Canalicular adenoma 
Duct papilloma 
CystadenomaCystadenocarcinoma 
Mucinous adenocarcinoma 
Oncocytic carcinoma 
Salivary duct carcinoma 
Myoepithelial carcinoma 
Carcinoma ex pleomorphic 
adenoma 
Salivary gland adenomas 
Pleomorphic adenoma 
Myoepithelioma 
Basal cell adenoma 
Soft tissue tumours 
Kaposi sarcoma 
Lymphangioma 
Ectomesenchymal chondromyxoid 
tumour 
Focal oral mucinosis 
Congenital granular cell epulis 
 
 
 
 
 
 
 
 
 
 
 
Haematolymphoid tumours 
Diffuse large B-cell lymphoma 
(DLBCL) 
Mantle cell lymphoma 
Follicular lymphoma 
Extranodal marginal zone B-cell 
lymphoma of MALT type 
Burkitt lymphoma 
T-cell lymphoma (including 
anaplastic large cell lymphoma 
Extramedullary plasmacytoma 
Langerhans cell histiocytosis 
Extramedullary myeloid sarcoma 
Follicular dendritic cell sarcoma / 
tumour 
Mucosal malignant melanoma 
Secondary tumours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE-II 
 
WHO HISTOLOGICAL CLASSIFICATION OF TUMOURS OF THE 
NASOPHARYNX 
 
Malignant epithelial tumours 
Nasopharyngeal carcinoma 
Nonkeratinizing carcinoma 
Keratinizing squamous cell carcinoma 
Basaloid squamous cell carcinoma 
Nasopharyngeal papillary adenocarcinoma 
Salivary gland-type carcinomas 
Benign epithelial tumours 
Hairy polyp 
Schneiderian-type papilloma 
Squamous papilloma 
Ectopic pituitary adenoma 
Salivary gland anlage tumour 
Craniopharyngioma 
Soft tissue neoplasms 
Nasopharyngeal angiofibroma 
Haematolymphoid tumours 
Hodgkin lymphoma 
Diffuse large B-cell lymphoma Extranodal NK/T cell lymphoma 
Follicular dendritic cell sarcoma/tumour X 
Extramedullary plasmacytoma 
Tumours of bone and cartilage 
Chordoma 
Secondary tumours 
 
 
 
 
ANNEXURE-III 
 
WHO HISTOLOGICAL CLASSIFICATION OF TUMOURS OF THE 
HYPOPHARYNX, LARYNX AND TRACHEA 
Malignant epithelial tumours 
Squamous cell carcinoma 
Verrucous carcinoma 
Basaloid squamous cell carcinoma 
Papillary squamous cell carcinoma 
Spindle cell carcinoma 
Acantholytic squamous cell 
carcinoma 
Adenosquamous carcinoma 
Lymphoepithelial carcinoma 
Giant cell carcinoma 
Malignant salivary gland-type tumours 
Mucoepidermoid carcinoma 
Adenoid cystic carcinoma 
Neuroendocrine tumours 
Typical carcinoid 
Atypical carcinoid 
Small cell carcinoma, 
neuroendocrine type 
Combined small cell carcinoma, 
neuroendocrine type 
 
Benign epithelial tumours 
Papilloma 
Papillomatosis 
Salivary gland-type adenomas 
Pleomorphic adenoma 
Oncocytic papillary cystadenoma 
Soft tissue tumours 
Malignant tumours 
Fibrosarcoma 
Malignant fibrous histiocytoma 
Liposarcoma 
Leiomyosarcoma 
Rhabdomyosarcoma 
Angiosarcoma 
Kaposi sarcoma 
Malignant peripheral nerve sheath 
tumour 
Synovial sarcoma 
Borderline tumours / LMP 
Inflammatory myofibroblastic 
Tumour 
 
 
 
 
 
 
 
Benign tumours 
Schwannoma 
Neurofibroma 
Lipoma 
Leiomyoma 
Rhabdomyoma 
Hemangioma 
Lymphangioma 
Granular cell tumour 
Haematolymphoid tumours 
Tumours of bone and cartilage 
Chondrosarcoma 
Osteosarcoma 
Chondroma 
Giant cell tumour 
Mucosal malignant melanoma 
Secondary tumours 
 
 
